Ivan Borbath
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · University hospital St-luc, Brussel · Cliniques Universitaires St-Luc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ivan Borbath as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06529718 · Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER · recruiting · Biliary Tract Cancer · principal investigator
- Ph3NCT05615818 · Personalized Medicine for Advanced Biliary Cancer PatientsUNICANCER · recruiting · Biliary Tract Neoplasms · principal investigator
- Ph2NCT05472259 · A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)Belgian Group of Digestive Oncology · recruiting · Metastatic Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph4NCT04140409 · Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation OptimisationCliniques universitaires Saint-Luc- Université Catholique de Louvain · terminated · Neuroendocrine Tumors, Carcinoid Syndrome · principal investigator
- Ph2NCT02958163 · Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)Cliniques universitaires Saint-Luc- Université Catholique de Louvain · terminated · Liver Neoplasms, Hepatocellular Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:38 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med · 200811,274 citationsRCR 270.2
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med · 20111,970 citationsRCR 52.9
- 884 citationsRCR 31.2
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol · 2018541 citationsRCR 17.7
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2022484 citationsRCR 33.1
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.Lancet Oncol · 2013477 citationsRCR 13.4
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol · 2021357 citationsRCR 19.4
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.Ann Oncol · 2017155 citationsRCR 5.6
- Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial.Gastroenterology · 2021140 citationsRCR 11.8
- 92 citationsRCR 3.6